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Abstract
Background: Sudden cardiac death (SCD) risk stratification is the most important preventive action in patients with
hypertrophic cardiomyopathy (HCM). The identification of the ischemia biomarker high sensitive troponin I (hs-TnI)
role for this arrhythmic disease may provide additional information for SCD risk stratification. The aim of the study
was to compare echocardiographic parameters (prognostic for risk stratification of SCD in HCM) among two
subgroups of HCM patients: with elevated hs-TnI versus non-elevated hs-TnI level.
Methods: In 51 HCM patients (mean age 39 ± 8 years, 31 males and 20 females) an echocardiographic
examination, including the stimulating maneuvers to provoke maximized LVOT gradient, was performed. The hs-TnI
was measured 24 h later.
Results: By comparing two subgroups of patients, 26 members with hs-TnI positive versus 25 with hs-TnI negative, the
study showed that the values of all three parameters were greater: provocable left ventricular outflow tract gradient
(LVOTG) – 49.1 ± 45.9 vs 25.5 ± 24.8 mmHg, p = 0.019; left atrial diameter – 50.1 ± 9.6 vs 43.9 ± 9.8 mmHg, p = 0.041;
maximal LV thickness – 22.1 ± 5.3 vs 19.9 ± 34 mm, p = 0.029.
Conclusion: The increased value of all three echocardiographic parameters used as risk factors for SCD (ESC Guidelines) is
related to the elevated level of hs-TnI in HCM. Due to the high LVOTG – great hs-TnI relationship, exercise stress, both
diagnostic and even rehabilitation/training, should be monitored by biomarker control.
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Background
Among risk factors of SCD in HCM in current ESC
Guidelines (1), three echocardiographic parameters are
included. These echocardiographic parameters are pre-
cise due to unequivocal, accurate measurable, in current
moment of risk stratification using risk calculator [1].
This calculator for sudden cardiac death risk does not
include any biomarker. Calculator also did not include
either the ischemic biomarker or signs and symptoms
for myocardial ischemia. However, ischemic response to
stress revealed by echocardiographic methods becomes
more and more important [2, 3].
Very recently, a relationship between nonsustained
ventricular tachycardia (ECG-Holter risk factor) and
elevated troponin level has been reported [4].
High-sensitive troponin I (hs-TnI) is aprecise bio-
marker for the detection of myocardial ischemia. In
previous HCM studies, the measurements of hs-Tn were
performed only at a resting (without stress) echocardiog-
raphy and not timely synchronized with maneuvers to
provoke LVOTG by natural stimuli reflecting daily
common physical activities for patients [5–8].
The aim of this study was compare to three echocar-
diographic parameters (risk factors for SCD: provocable
LVOTG, left atrial diameter, maximal LV thickness at
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end diastole) between subgroups divided by the border
value of h-s TnI concentrations in HCM patients. The cut--
off value 19,5 ng/l was used according to producer instruc-
tion (bioMerieux VIDAS® High sensitive Troponin I). The
99th percentile of a presumably healthy population, the
recommended cut-off has been defined at 19,5 ng/L [9].
We have compared echocardiographic parameters
between subgroup patients with elevated hs-TnI level
versus subgroup patients with non-elevated hs-TnI level.
Methods
Consecutive patients with HCM were recruited to the
study. All patients fulfilled conventional diagnostic
criteria for HCM. The exclusion criteria were as follows:
ST-segment or non-ST-segment elevation myocardial
infarction (recent or previous), significant coronary
stenosis on coronary angiography, or renal failure.
The final sample included 51 patients with HCM
(mean ± SD age, 39 ± 8 years; 30 men and 21 women).
Coronary angiography was performed (due to indica-
tions) in 11 patients (result was normal or insignificant
coronary artery stenosis <50%).
The patients on current pharmacotherapy were exam-
ined in the following 24-h cycle as follows: 8 a.m. echo-
cardiography with LVOTG provocation by natural
stimuli (orthostatic test and Valsalva test [1, 10–12]-
provocable LVOTG is more preference than resting in
SCD calculator [1]) day phase physical activity with
probably episodes of provocable LVOTG (unmeasur-
able), night phase period as a potential time for the rise
of troponin, which level has been measured after night
at 8 a.m. So far, no studies have used the following
protocol. The patients has been asked to performed your
common day physical activity and nocturnal resting.
This protocol seems to be reasonable because hs-TnI
levels may be related to the dynamic and labile nature of
LVOTG with fluctuating peaks during the day time
(provoked LVOTG as a potential cause for myocardial
ischemia). During the first stage of our study we did not
use upright exercise stress test to provoke LVOTG [12]
because previous study had reported exercise-related Tn
release [13].
Methodology of measurement of echocardiographic
parameters has been based on ESC Guidelines [1]: As
increased ventricular wall thickness can be found at any
location, the presence, distribution and severity of hyper-
trophy should be documented using a standardized
protocol for cross-sectional imaging from several projec-
tions. Correct orientation and beam alignment along
orthogonal planes are essential to avoid oblique sections
and over-estimation of wall thickness. Measurements of
LV wall thickness should be performed at end-diastole,
preferably in short-axis views. The most relevant param-
eter is the maximum LV wall thickness at any level [1].
Accordingly to ESC Guidelines [1] and previous Italian
publication [14] we use anteroposterior LA diameter.
The workflow of echocardiographic examination has
been as follows:
a) standard echo examination in resting condition in
supine position (the last stage of examination was
LVOTG measurement using 5-chamber apical
window).
b) immediately, Valsalva maneuver was perform in
supine position with LVOTG measurement
c) patients were asked to stand up with their left hand
on their head
d) LVOTG was measured in 5-chamber apical when
patient was in standing position
The study protocol was approved by the local institutional
review board (Komisja Bioetyki Jagiellonian University
KBET/119/B/2017). Informed consent was obtained from
each participant.
Statistical analysis
Normally distributed continuous variables were pre-
sented as mean ± SD. Differences between two groups
were assessed using independent t test. Correlations be-
tween hs-TnI levels and echocardiographic parameters
were assessed using the Pearson correlation coefficient.
A P value of less than 0.05 was considered significant.
Results
The characteristics of patients are displayed in Table 1.
Hs-TnI was detected in all HCM patients and patients
with an abnormal level > 19,5 ng/l were defined as
positive troponin subgroup.
By comparing the hs-TnI positive versus negative
subgroups, the values of all three parameters were
greater: left atrial diameter; maximal LV thickness,
provocable LVOTG. Also, resting LVOTG was greater in
hs-TnI positive subgroup (Table 2).
The Pearson correlations were statistically significant
between provocable LVOTG and hs-TnI (r = 0.39,
Table 1 Baseline characteristics of the patients
NYHA class 2.3 ± 0.7
CCS class 1.5 ± 0.5
Syncope 13
nsVT in Holter monitoring 16
Atrial fibrillation 9
Sudden death in family history 11
Creatinine, μg/l 88.2 ± 13.5
Systolic blood pressure mmHg at rest 129 ± 10
Diastolic blood pressure mmHg at rest 69 ± 8
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p < 0.05) as well as between resting LVOTG and hs-TnI
(r = 0.37 p < 0.05).
Discussion
Best to our knowledge, current study is the first ever re-
port about relationship between elevated hs-TnI and all
three echocardiographic risk factors (measurements was
timely synchronized) for sudden death in hypertrophic
cardiomyopathy (ESC Guidelines 2014).
The impact of stress echocardiography in HCM is
limited by the lack of standardization and outcome
data. ECS guidelines recommend stress echocardiog-
raphy solely for the evaluation of LVOT [1]. However,
large-scale registry data show that SE positivity for
ischemic criteria (such as new wall motion abnormal-
ities and coronary flow velocity reserve), rather than
inducible gradients predict adverse outcome in HCM
[2]. In a large study [2], mortality was predicted using
criteria for detecting ischemia on stress echocardiog-
raphy. The authors concluded that stress echocardiog-
raphy has an important prognostic role in patients
with HCM, with ischemic endpoints showing a
greater predictive accuracy than hemodynamic end-
points [2].
There is no unequivocal data regarding the
hemodynamic mechanism for myocardial ischemia diag-
nosed with hs-TnI release in HCM. We suspect that ele-
vated hs-TnI levels (related to episodes of provocable
LVOT) are quite common during the daily activities of
patients with HCM (even in pharmacotherapy). There-
fore, we investigate the presence of and potential
hemodynamic mechanism underlying the increased
hs-TnI levels in relation to the findings on resting and
provocable LVOTG.
Previously, in experimental studies (resting supine
position) ischemia was induced by rapid atrial pacing
and beta-receptor stimulation [15, 16]. Formerly, inva-
sive measured marker of myocardial ischemia was
lactate metabolism (myocardial lactate extraction indi-
cated the difference between arterial and great cardiac
vein lactate contents) [15, 16]. Negative difference was
defined as lactate production and preciously indicate
myocardial ischemia.
In HCM patients with LVOTG [15], transmural coron-
ary flow reserve was exhausted at a heart rate of 130
beats/min; higher heart rates resulted in more severe
metabolic evidence of ischemia (lactate production
instead consumption) with all patients experiencing
chest pain. At a heart rate of 150, most patients with
basal LVOTG demonstrated an actual decline in coron-
ary flow, which correlated with more severe metabolic
evidence of ischemia [15]. In a study by Cannon et al.
[17], majority patients with HCM with reversible
thallium-201 abnormalities during exercise showed
metabolic evidence of myocardial ischemia during rapid
pacing (myocardial lactate production) associated with
increase of LV end diastolic pressure. Beta-receptor
stimulation increased LVOTG parallel with lactate pro-
duction [16] and oppositely surgical reduction of
LVOTG was associated with a beneficial shift from
lactate production to consumption [18].
In previous study [19] ischemic injury assessed by CK-
MB (long-term follow-up was started in 1987/88 years)
was related with increasing left atrial diameter. In our
study without follow-up, we use more sensitive
biomarker and increased TnI level is related with greater
left atrial diameter.
Currently, we can use an almost a perfect marker of
ischemia, sampled from a peripheral vein i.e. troponin
measured by the high-sensitive method.
In a recent review by McCarthy et al. [20], the utility of
hs-Tn assessment in arrhythmic disease is only at the ini-
tial stage, but it has been proposed as a valuable screening
marker for patients with HCM at a high risk of SCD.
Regular training exercise has recently been recom-
mended for selected patients with HCM [21]. In our
opinion, based on the association between provocable
LVOTG and elevated troponin level in patients with
HCM, we suggest that any exercise stress test in HCM
patients (performed either for training or diagnostic
purposes) should be controlled by troponin level mea-
surements 6 and 12 h after the exercise).
Table 2 Comparison between hs-TnI negative and positive subgroup
Trop negative Trop positive
Parameters from echocardiography non-used as risk factors for SCD in calculator
LV end diastolic diameter (mm) 39.3 ± 6.6 42.1 ± 5.5 NS
Resting EF (%) 60.1 ± 11.7 62.6 ± 10.5 NS
Resting LVOTG (mmHg) 13.1 ± 12.7 33.9 ± 30 P = 0.021
Parameters from echocardiography used as risk factors for SCD in calculator
Provocable LVOTG (mmHg) 25.5 ± 24.8 49.1 ± 45.9 P = 0.019
Left atrial diameter (mm) 43.9 ± 9.8 50.1 ± 9.6 P = 0.041
Maximal LV thickness (mm) 19.9 ± 3.4 22.1 ± 5.3 P = 0.029
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Our study has several limitations. First, the current
pharmacological treatment was maintained, and particu-
larly β-blockers were not withdrawn. In our pilot study,
we aimed to make the first-ever observation on the
correlation between hs-TnI release and timely synchro-
nized findings on echocardiography. Our preliminary
study showed that β-blocker withdrawal or specially
performed exercise test might not be safe among this
group of patients. In future studies, we will attempt to
increase the dose and use only one type of a β-blocker
to decrease ischemia burden and the risk of troponin
release in exercise test. We are going to perform upright
exercise with LVOTG measurement at peak and post-
exercise in upright position [10, 22–24].
We decided to measure hs-TnI levels only once be-
cause our pilot study was conducted in an outpatient
setting. The optimal protocol, that is, 48-h profile of
troponin measurement with the assessment of troponin
with echocardiographic examination every 8 h, would re-
quire the in-hospital setting for the study and would be
more costly. Moreover, only an outpatient-based study
provides an opportunity to assess patients during their
common daily physical activities of patients, however
daily activities between the patients were not well
standardized by for example by questionnaire. The pa-
tients were asked to perform their common daily phys-
ical activities and nocturnal resting.
Conclusion
The increased value of all three echocardiographic
parameters using as risk factors for sudden death are re-
lated to the elevated level of h-s troponin-I in HCM.
Clinical perspective
These findings suggest that hs-Tn may be useful as an
additional biomarker for better risk stratification in HCM.
Additionally, we have postulated that every exercise test in
HCM should be controlled by the measurement of the
troponin level after 8–12 h from the stress test.
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